Caxton Associates LP Voyager Therapeutics, Inc. Transaction History

Caxton Associates LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$6.94 - $13.99 $101,039 - $203,680	-14,559 Reduced 39.82%	22,005 $251,000
Q1 2023 May 15, 2023	SELL	$6.0 - $10.78 $420,792 - $756,022	-70,132 Reduced 65.73%	36,564 $281,000
Q4 2022 Feb 14, 2023	SELL	$4.94 - $6.61 $147,686 - $197,612	-29,896 Reduced 21.89%	106,696 $650,000
Q1 2022 May 16, 2022	BUY	$2.75 - $9.44 $375,628 - $1.29 Million	136,592 New	136,592 $1.04 Million

130

34.7M

39.7K

34.6K

Ticker VYGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,647,600
Market Cap $207M
Description
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...

Get notified when there are updates to the investment portfolio of Caxton Associates LP, based on Form 13F filings with the SEC.

Stay updated on Caxton Associates LP with notifications on news.